- Home
- GHRS vs ARDX Comparison
GHRS vs ARDX Comparison
Compare GHRS & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- ARDX
- Stock Information
- Founded
- GHRS 2018
- ARDX 2007
- Country
- GHRS Ireland
- ARDX United States
- Employees
- GHRS N/A
- ARDX N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- ARDX Health Care
- Exchange
- GHRS Nasdaq
- ARDX Nasdaq
- Market Cap
- GHRS 960.2M
- ARDX 882.9M
- IPO Year
- GHRS 2021
- ARDX 2014
- Fundamental
- Price
- GHRS $14.38
- ARDX $4.34
- Analyst Decision
- GHRS Strong Buy
- ARDX Strong Buy
- Analyst Count
- GHRS 8
- ARDX 9
- Target Price
- GHRS $30.63
- ARDX $10.17
- AVG Volume (30 Days)
- GHRS 353.0K
- ARDX 4.1M
- Earning Date
- GHRS 09-02-2025
- ARDX 08-04-2025
- Dividend Yield
- GHRS N/A
- ARDX N/A
- EPS Growth
- GHRS N/A
- ARDX N/A
- EPS
- GHRS N/A
- ARDX N/A
- Revenue
- GHRS N/A
- ARDX $361,706,000.00
- Revenue This Year
- GHRS N/A
- ARDX $11.39
- Revenue Next Year
- GHRS N/A
- ARDX $32.84
- P/E Ratio
- GHRS N/A
- ARDX N/A
- Revenue Growth
- GHRS N/A
- ARDX 127.33
- 52 Week Low
- GHRS $6.00
- ARDX $3.21
- 52 Week High
- GHRS $20.50
- ARDX $7.18
- Technical
- Relative Strength Index (RSI)
- GHRS 46.75
- ARDX 52.69
- Support Level
- GHRS $12.81
- ARDX $4.21
- Resistance Level
- GHRS $15.28
- ARDX $4.47
- Average True Range (ATR)
- GHRS 1.49
- ARDX 0.17
- MACD
- GHRS -0.41
- ARDX -0.04
- Stochastic Oscillator
- GHRS 20.60
- ARDX 21.78
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.